Revenio Group: New long-term opportunities created
Revenio's Q1 report was very strong, especially in terms of profitability, and the long-term story continues to progress convincingly. On Wednesday, the company told about an interesting opportunity in AI, which opens new growth opportunities for the company. However, our estimates for the next few years remain largely unchanged and the share valuation (2023e P/E 55x and EV/EBIT 43x) is very high. In the long term, the expected very strong earnings growth will correct even the higher valuation multiples, but due to the strong headwind of growth companies’ pricing, we still see risks in the valuation and refrain from further purchases.
Login required
This content is only available for logged in users
Revenio Group
Revenio är verksamt inom medicinteknik. Inom koncernen återfinns forskning och utveckling av tryckmätningsteknik som används vid behandling av ett flertal sjukdomar såsom glaukom, osteoporos, hudcancer samt astma. Verksamhet innehas på global nivå och drivs via flertalet dotterbolag med vardera affärsinriktning. Bolagets huvudkontor ligger i Vantaa.
Read more on company pageKey Estimate Figures29.04.2022
2021 | 22e | 23e | |
---|---|---|---|
Omsättning | 78,8 | 95,7 | 115,9 |
tillväxt-% | 29,07 % | 21,49 % | 21,03 % |
EBIT (adj.) | 24,5 | 29,1 | 37,2 |
EBIT-% | 31,13 % | 30,39 % | 32,13 % |
EPS (adj.) | 0,74 | 0,87 | 1,08 |
Utdelning | 0,34 | 0,46 | 0,57 |
Direktavkastning | 0,61 % | 1,60 % | 1,99 % |
P/E (just.) | 75,13 | 32,59 | 26,39 |
EV/EBITDA | 57,67 | 24,18 | 18,87 |